Dksortho & Sharma Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 4.00 Cr
as on 23-10-2024
- Paid Up Capital ₹ 4.00 Cr
as on 23-10-2024
- Company Age 20 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 20.02 Cr
as on 23-10-2024
- Satisfied Charges ₹ 32.02 Cr
as on 23-10-2024
- Revenue 47.46%
(FY 2023)
- Profit 932.94%
(FY 2023)
- Ebitda -15.38%
(FY 2023)
- Net Worth 2.42%
(FY 2023)
- Total Assets -1.04%
(FY 2023)
About Dksortho & Sharma Pharmaceutical
The Corporate was formerly known as Sharma Pharmaceutical Private Limited. The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 4.00 Cr and a paid-up capital of Rs 4.00 Cr.
The company currently has active open charges totaling ₹20.02 Cr. The company has closed loans amounting to ₹32.02 Cr, as per Ministry of Corporate Affairs (MCA) records.
Seemakumari Sharma and Smriti Kumari serve as directors at the Company.
- CIN/LLPIN
U33100GJ2004PTC043834
- Company No.
043834
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Mar 2004
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Vadodara, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Dksortho & Sharma Pharmaceutical?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Seemakumari Sharma  | Director | 23-Mar-2004 | Current |
| Smriti Kumari | Director | 15-Apr-2024 | Current |
Financial Performance of Dksortho & Sharma Pharmaceutical.
Dksortho & Sharma Pharmaceutical Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 47.46% increase. The company also saw a substantial improvement in profitability, with a 932.94% increase in profit. The company's net worth moved up by a moderate rise of 2.42%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dksortho & Sharma Pharmaceutical?
In 2023, Dksortho & Sharma Pharmaceutical had a promoter holding of 100.00%. The company had 1 Subsidiary. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 13 Oct 2023 | ₹9.00 M | Open |
Others Creation Date: 11 Dec 2019 | ₹2.50 M | Open |
Others Creation Date: 23 Dec 2017 | ₹1.00 Cr | Open |
How Many Employees Work at Dksortho & Sharma Pharmaceutical?
Dksortho & Sharma Pharmaceutical has a workforce of 35 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dksortho & Sharma Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dksortho & Sharma Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
